Lobaplatin

&NA;,

doi:10.2165/00126839-200304060-00008

Cited by 31 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compound was initially developed by ASTA Medica in Germany under the name D-19466, but was later acquired by the German company Zentaris AG, a subsidiary of the Canadian biopharmaceutical company Æterna Zentaris. Zentaris eventually sold Hainan Tianwang (Chang’an) International Pharmaceutical the rights to manufacture and market the drug in China . Although clinical trials were initially carried out in Europe, the United States, Australia, Brazil, and South Africa to examine efficacy in patients with a range of different cancers, regulatory approval was only obtained in China.…”

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

“…Although clinical trials were initially carried out in Europe, the United States, Australia, Brazil, and South Africa to examine efficacy in patients with a range of different cancers, regulatory approval was only obtained in China. Lobaplatin is approved primarily for the treatment of chronic myelogenous leukemia, but is also used in patients suffering from small cell lung cancer and metastatic breast cancer . Although literature sources and press releases indicate that lobaplatin had already received regulatory approval in 2003, ,, the Chinese FDA State Food and Drug Administration Database lists the approval year as 2010…”

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

“…Lobaplatin is approved primarily for the treatment of chronic myelogenous leukemia, but is also used in patients suffering from small cell lung cancer and metastatic breast cancer . Although literature sources and press releases indicate that lobaplatin had already received regulatory approval in 2003, ,, the Chinese FDA State Food and Drug Administration Database lists the approval year as 2010…”

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

See 2 more Smart Citations

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.

show abstract

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

See 1 more Smart Citation

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

show abstract

“…Lobaplatin (chemical name: 1,2-cyclobutanedimethanamine-N,N’) is the third-generation platinum-based anti-cancer compound developed by ASTA Medical (Degussa, German). The anti-tumor mechanism of lobaplatin is similar to other platinum agents, forming DNA intra-strand and/or inter-strand cross-linking and, therefore, affecting the normal functions of DNA and achieving the purpose of inhibiting tumor 16. It was showed in preclinical studies that the anti-cancer therapeutic index of lobaplatin equaled or was higher than cisplatin and carboplatin; also, lobaplatin was effective for partial tumors with cisplatin and carboplatin resistance, had lower renal toxicity than cisplatin and incomplete cross resistance with other platinum agents, and showed better anti-tumor activity in preclinical studies 17–19.…”

Section: Discussionmentioning

confidence: 99%

<p>Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer</p>

Wu¹,

Xu²,

Yan³

et al. 2019

OTT

View full text Add to dashboard Cite

Objective To study the efficacy and adverse reactions of lobaplatin combined with other chemotherapy drugs in the treatment of metastatic breast cancer. Methods This retrospective analysis enrolled 114 patients who were diagnosed with advanced breast cancer from January 2010 to December 2015. Lobaplatin and another chemotherapeutic agent were given to patients. The efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results Therapeutic efficacy and adverse reactions could be evaluated in 112 patients with 2 complete response (CR) patients, 31 cases of partial response (PR), 52 cases of stable disease (SD) and 27 cases of progressive disease (PD). The overall response rate (ORR) was 29.5% and the disease control rate (DCR) was 75.9%. The median time to progression (TTP) was 7.7 months, and the median overall survival (OS) was expected to be 28.0 months. The main side effects were myelosuppression. Twenty five patients (21.9%) had grade 3/4 neutrophil suppression, 18 patients (15.8%) had grade 3/4 thrombocytopenia. Other toxicities included gastrointestinal reaction, peripheral neuropathy, stomatitis, hepatic dysfunction, fatigue and skin rashes, which were alleviated by symptomatic treatment. Conclusion Lobaplatin-based regimen chemotherapy for advanced metastatic breast cancer patients is effective and well tolerated.

show abstract

Platinum

Lansdown

2023

Patty's Toxicology

View full text Add to dashboard Cite

Platinum is ubiquitous in the human environment and is present in plants and animals, human food chains, airborne particles in inner‐city areas, and factory environments. It is a rare transitional metal with many uses in medicine, dentistry, and industrial applications. These include catalytic converters, electrical engineering, computers, space science, chemical syntheses, and jewelry. Platinum forms numerous durable alloys for clinical and industrial applications, and very many inorganic and organic compounds some of which are profound oxidizing agents and corrosive to skin and eyes. Others like the co‐ordination complexes, which are antimitotic through DNA binding, are potent anticancer drugs. The toxicity profile for platinum compounds is incomplete but permitted exposure levels (PEL) are shown for key materials. Respiratory distress, allergy, and hypersensitivity are principal hazards encountered through inhalation of airborne nanoparticles in mining, recycling, and emissions from vehicle exhaust systems. Metabolic pathways and excretion patterns involving liver and kidneys are discussed in relation to population studies. Urine analyses are clinical measures of platinum exposure. The anticancer/antimitotic drugs including cis ‐platin and carboplatin are clinically efficacious but cause nephrotoxicity, ear and sensi‐neural hearing, and possible carcinogenicity. Children are more sensitive. Experiments in animal models and cultured cells have contributed little in the understanding of hazards associated with platinum and related compounds. Whilst evidence of mutagenicity, DNA binding, clastogenicity is presented in standard laboratory screens, the 15th National Toxicology Program, Report on Carcinogens (2021) states that cis ‐platin should be reasonably anticipated to be a human carcinogen, despite no conclusive human epidemiological studies being available.

show abstract

Lobaplatin

Cited by 31 publications

References 5 publications

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

<p>Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer</p>

Platinum

Contact Info

Product

Resources

About